SG11201706940QA - Chimeric antigen receptor - Google Patents

Chimeric antigen receptor

Info

Publication number: SG11201706940QA
Authority: SG; Singapore
Prior art keywords: antigen receptor; chimeric antigen; chimeric; receptor; antigen
Prior art date: 2015-03-23

Application number

SG11201706940QA

Other languages

English (en)

Inventor

Martin Pulé

Shaun Cordoba

Original Assignee

Ucl Business Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-03-23

Filing date

2016-03-22

Publication date

2017-09-28

2016-03-22 Application filed by Ucl Business Plc filed Critical Ucl Business Plc

2017-09-28 Publication of SG11201706940QA publication Critical patent/SG11201706940QA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG11201706940QA 2015-03-23 2016-03-22 Chimeric antigen receptor SG11201706940QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1504840.8A GB201504840D0 (en)	2015-03-23	2015-03-23	Chimeric antigen receptor
PCT/GB2016/050795 WO2016151315A1 (en)	2015-03-23	2016-03-22	Chimeric antigen receptor

Publications (1)

Publication Number	Publication Date
SG11201706940QA true SG11201706940QA (en)	2017-09-28

Family

ID=53052211

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201706940QA SG11201706940QA (en)	2015-03-23	2016-03-22	Chimeric antigen receptor

Country Status (21)

Country	Link
US (1)	US11058722B2 (he)
EP (1)	EP3274366B8 (he)
JP (3)	JP6675417B2 (he)
KR (1)	KR102174280B1 (he)
CN (1)	CN107406518B (he)
AU (1)	AU2016238583B2 (he)
BR (1)	BR112017018252A2 (he)
CA (1)	CA2978852C (he)
CL (1)	CL2017002413A1 (he)
DK (1)	DK3274366T3 (he)
ES (1)	ES2773527T3 (he)
GB (1)	GB201504840D0 (he)
HU (1)	HUE047929T2 (he)
IL (1)	IL254254B (he)
MX (1)	MX371384B (he)
PL (1)	PL3274366T3 (he)
PT (1)	PT3274366T (he)
RU (1)	RU2752880C2 (he)
SG (1)	SG11201706940QA (he)
WO (1)	WO2016151315A1 (he)
ZA (1)	ZA201705682B (he)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9511092B2 (en)	2013-01-28	2016-12-06	St. Jude Children's Research Hospital, Inc.	Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
US11982673B2 (en)	2014-03-05	2024-05-14	Autolus Limited	Methods
US11385233B2 (en)	2015-03-05	2022-07-12	Autolus Limited	Methods of depleting malignant T-cells
GB201403972D0 (en)	2014-03-06	2014-04-23	Ucl Business Plc	Chimeric antigen receptor
GB201405845D0 (en)	2014-04-01	2014-05-14	Ucl Business Plc	Signalling system
SG11201609118RA (en)	2014-05-15	2016-11-29	Univ Singapore	Modified natural killer cells and uses thereof
GB201415347D0 (en)	2014-08-29	2014-10-15	Ucl Business Plc	Signalling system
GB201501936D0 (en) *	2015-02-05	2015-03-25	Ucl Business Plc	Signalling system
SG10201914069SA (en)	2015-05-18	2020-03-30	Tcr2 Therapeutics Inc	Compositions and methods for tcr reprogramming using fusion proteins
US11446398B2 (en)	2016-04-11	2022-09-20	Obsidian Therapeutics, Inc.	Regulated biocircuit systems
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor
JP7109789B2 (ja)	2016-08-02	2022-08-01	ティーシーアール２セラピューティクスインク．	融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
PT3445787T (pt)	2016-10-07	2021-03-15	Tcr2 Therapeutics Inc	Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão
AU2017363311A1 (en)	2016-11-22	2019-06-13	TCR2 Therapeutics Inc.	Compositions and methods for TCR reprogramming using fusion proteins
WO2018182511A1 (en)	2017-03-27	2018-10-04	National University Of Singapore	Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
KR20240057444A (ko)	2017-03-27	2024-05-02	내셔널 유니버시티 오브 싱가포르	절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
WO2018176144A1 (en) *	2017-03-29	2018-10-04	Sunnybrook Research Institute	Engineered t-cell modulating molecules and methods of using same
US11166985B2 (en)	2017-05-12	2021-11-09	Crispr Therapeutics Ag	Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3621981A2 (en)	2017-05-12	2020-03-18	CRISPR Therapeutics AG	Materials and methods for engineering cells and uses thereof in immuno-oncology
AU2018311345A1 (en) *	2017-08-02	2020-02-27	Autolus Limited	Cells expressing a chimeric antigen receptor or engineered TCR and comprising a nucleotide sequence which is selectively expressed
EP3704150A1 (en) *	2017-11-01	2020-09-09	F. Hoffmann-La Roche AG	The compbody - a multivalent target binder
GB201801831D0 (en) *	2018-02-05	2018-03-21	Autolus Ltd	Chimeric receptor
CA3089170A1 (en)	2018-02-09	2019-08-15	National University Of Singapore	Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
AU2019266398A1 (en)	2018-05-11	2020-11-19	Crispr Therapeutics Ag	Methods and compositions for treating cancer
CA3099831A1 (en)	2018-05-15	2019-11-21	Autolus Limited	Chimeric antigen receptor
GB201807870D0 (en)	2018-05-15	2018-06-27	Autolus Ltd	A CD79-specific chimeric antigen receptor
CA3109630A1 (en) *	2018-08-16	2020-02-20	Memorial Sloan-Kettering Cancer Center	Leucine zipper-based compositions and methods of use
CN109265550B (zh) *	2018-09-25	2020-09-15	华东师范大学	Bcma抗体、嵌合抗原受体和药物
FI3856775T3 (fi)	2018-09-27	2024-12-04	Autolus Ltd	Kimeerinen antigeenireseptori
JP2022504191A (ja) *	2018-10-05	2022-01-13	ザンクトアンナキンダークレプスフォルシュング	キメラ抗原受容体（ｃａｒ）群
US20220041718A1 (en)	2018-10-31	2022-02-10	Autolus Limited	Binding domain
CA3131533A1 (en)	2019-03-05	2020-09-10	Nkarta, Inc.	Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN113597328A (zh)	2019-03-21	2021-11-02	瑞泽恩制药公司	用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
BR112021021542A2 (pt)	2019-04-30	2022-04-19	Crispr Therapeutics Ag	Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19
GB201919017D0 (en)	2019-12-20	2020-02-05	Autolus Ltd	Cell
CN111234033B (zh) *	2020-01-21	2021-05-11	南京北恒生物科技有限公司	多链嵌合抗原受体及其用途
GB202004263D0 (en)	2020-03-24	2020-05-06	Autolus Ltd	Antibody conjugate
GB202005216D0 (en)	2020-04-08	2020-05-20	Autolus Ltd	Cell
GB202006820D0 (en)	2020-05-07	2020-06-24	Autolus Ltd	Cell
GB202017649D0 (en)	2020-11-09	2020-12-23	Autolus Ltd	Polypeptide
KR20230148837A (ko)	2021-02-25	2023-10-25	라이엘 이뮤노파마, 인크.	Ror1 표적화 키메라 항원 수용체
WO2022204326A1 (en) *	2021-03-24	2022-09-29	The Regents Of The University Of California	Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
GB202115329D0 (en) *	2021-10-25	2021-12-08	Autolus Ltd	Chimeric cytokine receptor
WO2024019961A1 (en) *	2022-07-18	2024-01-25	Cargo Therapeutics, Inc.	Cd2 recruiting chimeric antigen receptors and fusion proteins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7081443B2 (en)	2002-05-21	2006-07-25	Korea Advanced Institutes Of Science And Technology (Kaist)	Chimeric comp-ang1 molecule
WO2010102518A1 (zh) *	2009-03-13	2010-09-16	北京表源生物技术有限公司	一种融合蛋白多聚体
KR101156085B1 (ko) *	2010-01-29	2012-06-20	국립암센터	４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도
US10745467B2 (en) *	2010-03-26	2020-08-18	The Trustees Of Dartmouth College	VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2013051718A1 (ja) *	2011-10-07	2013-04-11	国立大学法人三重大学	キメラ抗原受容体
KR102247979B1 (ko) *	2012-05-25	2021-05-04	셀렉티스	면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
KR102141259B1 (ko) *	2012-09-04	2020-08-05	셀렉티스	멀티―체인 키메라 항원 수용체 및 그것의 용도들
EP2956175B1 (en) *	2013-02-15	2017-10-04	The Regents of the University of California	Chimeric antigen receptor and methods of use thereof
CN103145849B (zh) *	2013-02-18	2014-06-11	冯振卿	嵌合抗原受体及其用途
US10494434B2 (en) *	2013-12-20	2019-12-03	Fred Hutchinson Cancer Research Center	Tagged chimeric effector molecules and receptors thereof
CA2936501A1 (en)	2014-01-13	2015-07-16	Stephen J. Forman	Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use
GB201415347D0 (en)	2014-08-29	2014-10-15	Ucl Business Plc	Signalling system
GB201610512D0 (en)	2016-06-16	2016-08-03	Autolus Ltd	Chimeric antigen receptor

2015
- 2015-03-23 GB GBGB1504840.8A patent/GB201504840D0/en not_active Ceased
2016
- 2016-03-22 MX MX2017010552A patent/MX371384B/es active IP Right Grant
- 2016-03-22 AU AU2016238583A patent/AU2016238583B2/en active Active
- 2016-03-22 HU HUE16712424A patent/HUE047929T2/hu unknown
- 2016-03-22 EP EP16712424.7A patent/EP3274366B8/en active Active
- 2016-03-22 US US15/560,558 patent/US11058722B2/en active Active
- 2016-03-22 PL PL16712424T patent/PL3274366T3/pl unknown
- 2016-03-22 DK DK16712424.7T patent/DK3274366T3/da active
- 2016-03-22 WO PCT/GB2016/050795 patent/WO2016151315A1/en active Application Filing
- 2016-03-22 BR BR112017018252-1A patent/BR112017018252A2/pt active Search and Examination
- 2016-03-22 KR KR1020177030391A patent/KR102174280B1/ko active Active
- 2016-03-22 PT PT167124247T patent/PT3274366T/pt unknown
- 2016-03-22 CA CA2978852A patent/CA2978852C/en active Active
- 2016-03-22 JP JP2017549766A patent/JP6675417B2/ja active Active
- 2016-03-22 CN CN201680017370.3A patent/CN107406518B/zh active Active
- 2016-03-22 RU RU2017132978A patent/RU2752880C2/ru active
- 2016-03-22 SG SG11201706940QA patent/SG11201706940QA/en unknown
- 2016-03-22 ES ES16712424T patent/ES2773527T3/es active Active
2017
- 2017-08-21 ZA ZA2017/05682A patent/ZA201705682B/en unknown
- 2017-08-31 IL IL254254A patent/IL254254B/he active IP Right Grant
- 2017-09-25 CL CL2017002413A patent/CL2017002413A1/es unknown
2020
- 2020-01-09 JP JP2020001971A patent/JP2020048588A/ja not_active Withdrawn
2022
- 2022-12-16 JP JP2022201192A patent/JP2023021396A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DK3274366T3 (da)	2020-02-10
CN107406518A (zh)	2017-11-28
KR102174280B1 (ko)	2020-11-04
CL2017002413A1 (es)	2018-03-16
NZ735267A (en)	2021-04-30
CN107406518B (zh)	2022-02-01
IL254254B (he)	2021-04-29
PL3274366T3 (pl)	2020-06-15
GB201504840D0 (en)	2015-05-06
KR20180009738A (ko)	2018-01-29
US20180050065A1 (en)	2018-02-22
IL254254A0 (he)	2017-10-31
WO2016151315A1 (en)	2016-09-29
ZA201705682B (en)	2018-12-19
MX2017010552A (es)	2018-03-14
EP3274366B1 (en)	2019-12-11
AU2016238583B2 (en)	2020-08-13
JP2018510639A (ja)	2018-04-19
MX371384B (es)	2020-01-28
CA2978852A1 (en)	2016-09-29
RU2017132978A (ru)	2019-04-08
JP2020048588A (ja)	2020-04-02
RU2017132978A3 (he)	2019-06-24
PT3274366T (pt)	2020-01-30
BR112017018252A2 (pt)	2018-04-10
CA2978852C (en)	2021-10-19
HUE047929T2 (hu)	2020-05-28
JP2023021396A (ja)	2023-02-10
US11058722B2 (en)	2021-07-13
RU2752880C2 (ru)	2021-08-11
ES2773527T3 (es)	2020-07-13
AU2016238583A1 (en)	2017-09-28
EP3274366A1 (en)	2018-01-31
EP3274366B8 (en)	2020-02-12
JP6675417B2 (ja)	2020-04-01

Publication	Publication Date	Title
IL254254A0 (he)	2017-10-31	קולטן אנטיגן כימרי
GB201503742D0 (en)	2015-04-22	Chimeric antigen receptor
IL250536A0 (he)	2017-03-30	קולטני אנטיגן כימרים
IL258527A (he)	2018-05-31	קולטני אנטיגן כימריים נגד קבוצת מיון 30
IL251030A0 (he)	2017-04-30	קולטני אנטיגן כימרים
SG11201606790XA (en)	2016-09-29	Chimeric antigen receptor
PT3294764T (pt)	2021-02-15	Composições de recetores de antigénios quiméricos
IL252783A0 (he)	2017-08-31	קולטני אנטיגן כימרי bcma
IL250202A0 (he)	2017-03-30	קולטני אנטיגן כימרים bcma
GB201607968D0 (en)	2016-06-22	Chimeric antigen receptor
GB201617290D0 (en)	2016-11-23	Novel chimeric antigen receptors
EP3256496A4 (en)	2018-12-12	Chimeric antigen receptors
GB201610512D0 (en)	2016-08-03	Chimeric antigen receptor
ZA201906321B (en)	2021-02-24	Chimeric antigen receptor
GB201709508D0 (en)	2017-08-02	Chimeric antigen receptor
GB201519900D0 (en)	2015-12-23	Chimeric antigen receptor
GB201810451D0 (en)	2018-08-08	Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201721421D0 (en)	2018-01-31	Chimeric antigen receptor
GB201612844D0 (en)	2016-09-07	Chimeric antigen receptor
GB201612533D0 (en)	2016-08-31	Chimeric antigen receptor
GB201604387D0 (en)	2016-04-27	Chimeric antigen receptor
GB201409761D0 (en)	2014-07-16	Chimeric antigen receptor
GB201403481D0 (en)	2014-04-16	Chimeric antigen receptor